Abstract: Tracking a tagged object may include receiving, using a first processor, a first video of an object tagged with a radio frequency identification (RFID) tag and first metadata read from the RFID tag. The first metadata may be stored in association with the first video using the first processor. First updated metadata may be written to the RFID tag using the first processor. The first updated metadata may specify at least one of a time the first video is received or a location of the first processor.

Abstract: Tracking a tagged object may include receiving, using a first processor, a first video of an object tagged with a radio frequency identification (RFID) tag and first metadata read from the RFID tag. The first metadata may be stored in association with the first video using the first processor. First updated metadata may be written to the RFID tag using the first processor. The first updated metadata may specify at least one of a time the first video is received or a location of the first processor.

Abstract: Tracking a tagged object may include receiving, using a first processor, a first video of an object tagged with a radio frequency identification (RFID) tag and first metadata read from the RFID tag. The first metadata may be stored in association with the first video using the first processor. First updated metadata may be written to the RFID tag using the first processor. The first updated metadata may specify at least one of a time the first video is received or a location of the first processor.

Abstract: A method, system and computer program product for detecting allergens present in a product. A tag (e.g., passive RFID tag) receives a query from the user of a computing device containing a list of allergens to determine if an allergen is present in the product (e.g., product for ingestion). Product information associated with the product in stored in secure memory (e.g., write-only memory) on the tag. The tag determines if an allergen to the user is present in the product using the list of allergens in the query as well as the product information associated with the product. The tag then notifies the user of the computing device regarding whether an allergen to the user is present in the product based on the determination. In this manner, allergens are detected in a product and made known to the user.

Abstract: Tracking a tagged object may include receiving, using a first processor, a first video of an object tagged with a radio frequency identification (RFID) tag and first metadata read from the RFID tag. The first metadata may be stored in association with the first video using the first processor. First updated metadata may be written to the RFID tag using the first processor. The first updated metadata may specify at least one of a time the first video is received or a location of the first processor.

Abstract: This invention relates to stable non-aqueous formulations which are suspensions of proteinaceous substances or nucleic acids in non-aqueous, anhydrous, aprotic, hydrophobic, non-polar vehicles with low reactivity. More specifically, the present invention relates to stable protein or nucleic acid formulations wherein the compound remains in stable, dry powder form, yet the formulation is flowable and, therefore amenable to delivery to an animal via injection transdermal administration, oral delivery or using an implantable device for sustained delivery. These stable formulations may be stored at elevated temperatures (e.g., 37° C.) for long periods of time and are especially useful as flowable formulations which can be shipped and/or stored at high temperatures or in implantable delivery devices for long term delivery (e.g., 1-12 months or longer) of drug.

Abstract: This invention relates to stable non-aqueous formulations which are suspensions of proteinaceous substances or nucleic acids in non-aqueous, anhydrous, aprotic, hydrophobic, non-polar vehicles with low reactivity. More specifically, the present invention relates to stable protein or nucleic acid formulations wherein the compound remains in stable, dry powder form, yet the formulation is flowable and, therefore amenable to delivery to an animal via injection, transdermal administration, oral delivery or using an implantable device for sustained delivery. These stable formulations may be stored at elevated temperatures (e.g., 37° C.) for long periods of time and are especially useful as flowable formulations which can be shipped and/or stored at high temperatures or in implantable delivery devices for long term delivery (e.g., 1-12 months or longer) of drug.

Abstract: This invention relates to stable non-aqueous formulations which are suspensions of proteinaceous substances or nucleic acids in non-aqueous, anhydrous, aprotic, hydrophobic, non-polar vehicles with low reactivity. More specifically, the present invention relates to stable protein or nucleic acid formulations wherein the compound remains in stable, dry powder form, yet the formulation is flowable and, therefore amenable to delivery to an animal via injection, transdermal administration, oral delivery or using an implantable device for sustained delivery. These stable formulations may be stored at elevated temperatures (e.g., 37° C.) for long periods of time and are especially useful as flowable formulations which can be shipped and/or stored at high temperatures or in implantable delivery devices for long term delivery (e.g., 1-12 months or longer) of drug.

Abstract: This invention relates to stable non-aqueous formulations which are suspensions of proteinaceous substances or nucleic acids in non-aqueous, anhydrous, aprotic, hydrophobic, non-polar vehicles with low reactivity. More specifically, the present invention relates to stable protein or nucleic acid formulations wherein the compound remains in stable, dry powder form, yet the formulation is flowable and, therefore amenable to delivery to an animal via injection, transdermal administration, oral delivery or using an implantable device for sustained delivery. These stable formulations may be stored at elevated temperatures (e.g., 37° C.) for long periods of time and are especially useful as flowable formulations which can be shipped and/or stored at high temperatures or in implantable delivery devices for long term delivery (e.g., 1-12 months or longer) of drug.